Antimicrobial Peptide DP7 Boosts Antibiotic Effectiveness Against Drug-Resistant Bacteria

DP7 demonstrated potent antimicrobial activity on its own against all tested clinical isolates, with minimum inhibitory concentrations at or below 32 mg/L. When combined with vancomycin or azithromycin, the effects were frequently synergistic rather than merely additive. Notably, the synergy between DP7 and azithromycin was strongest against the most resistant strains — those carrying two or more azithromycin-resistance genes (ermA, ermB, ermC, mefA, msrA). Electron microscopy showed no major structural damage to bacteria, suggesting the synergistic mechanism operates at the molecular level rather than through physical membrane destruction.

Researchers used the checkerboard method to evaluate synergy between two antimicrobial peptides (DP7 and CLS001) and four antibiotics (gentamicin, vancomycin, azithromycin, and amoxicillin) against clinical isolates of S. aureus, P. aeruginosa, A. baumannii, and E. coli. Resistance genes were identified using quantitative PCR. Transmission electron microscopy was used to examine bacterial morphology after combination treatment.

With antibiotic resistance rising globally and few new antibiotics in development, finding ways to make existing antibiotics work again is critical. This study shows that pairing a peptide with traditional antibiotics can restore effectiveness against bacteria that have become resistant — offering a potential combination therapy strategy against superbugs.

Antimicrobial peptides represent one of the most promising approaches to the antibiotic resistance crisis. Rather than replacing antibiotics entirely, this research supports the strategy of using peptides as 'antibiotic boosters' — agents that restore the effectiveness of drugs that bacteria have learned to resist.

This was an in vitro (lab dish) study, so results may not directly translate to treating infections in living organisms. The number of clinical isolates tested for each species was limited. The molecular mechanism behind the DP7-azithromycin synergy was not fully elucidated. No animal infection models or toxicity data were reported.